Position in MRNA
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$248,116
+$21,904 QoQ
Shares Held
3,543
-20.4% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.06%
of 13F equity value
Holder Rank
#469
of 772 holders
Holding Since
Dec 2023
11 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in MRNA Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Rakuten Securities, Inc. holds $795,216 across 27 Biotechnology names. MRNA ranks #1 (31.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MRNA |
Moderna, Inc.
This page
|
3,543 | $248,116 | |
| 2 | LEGN |
Legend Biotech Corp
|
8,005 | $231,184 | |
| 3 | RVMD |
Revolution Medicines, Inc.
|
350 | $65,548 | |
| 4 | CRSP |
CRISPR Therapeutics AG
|
731 | $39,868 | |
| 5 | BNTX |
BioNTech SE
|
416 | $38,708 | |
| 6 | RPRX |
Royalty Pharma plc
|
561 | $31,455 | |
| 7 | JAZZ |
Jazz Pharmaceuticals plc
|
115 | $27,711 | |
| 8 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
30 | $16,108 |
All Filings in MRNA
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $248,116 | 3,543 | Shares | Defined | 2026-08-12 | |
| 2026-03-31 | $226,212 | 4,453 | Shares | Defined | 2026-05-01 | |
| 2025-12-31 | $104,571 | 3,546 | Shares | Defined | 2026-01-29 | |
| 2025-09-30 | $559,477 | 21,660 | Shares | Defined | 2025-10-28 | |
| 2025-06-30 | $615,450 | 22,307 | Shares | Defined | 2025-08-15 | |
| 2025-03-31 | $741,636 | 26,160 | Shares | Defined | 2025-04-18 | |
| 2024-12-31 | $311,808 | 7,499 | Shares | Defined | 2025-02-10 | |
| 2024-09-30 | $62,887 | 941 | Shares | Defined | 2024-11-05 | |
| 2024-06-30 | $19,356 | 163 | Shares | Defined | 2024-07-31 | |
| 2024-03-31 | $48,271 | 453 | Shares | Defined | 2024-05-01 | |
| 2023-12-31 | $107,306 | 1,079 | Shares | Defined | 2024-01-31 | |
| No filing history on record for this holder in this stock. | ||||||